Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.37 |
| ▸ | FEN1 | P39748 | 7/20 | 0.37 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25791777 | 0.92 | KMO (0.44) | CYP2C19CYP17A1KMOALOX5APFEN1 | |
| SCHEMBL14990759 | 0.88 | HTR2C (0.41) | CYP2C19CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL30443759 | 0.87 | KMO (0.36) | CYP2C19CYP17A1KMOALOX5APFEN1 | |
| SCHEMBL17613226 | 0.85 | CYP2C19 (0.41) | CYP2C19CYP17A1KMOALOX5APFEN1 | |
| SCHEMBL31749710 | 0.83 | CYP2C19 (0.38) | CYP2C19CYP17A1ALOX5APFEN1ELOVL1 | |
| SCHEMBL30549079 | 0.81 | ALOX5AP (0.33) | CYP2C19CYP17A1KMOALOX5APFEN1 | |
| SCHEMBL15025645 | 0.80 | KMO (0.41) | CYP2C19CYP17A1KMO | |
| SCHEMBL22121978 | 0.79 | ALOX5AP (0.38) | KMOALOX5APFEN1ELOVL1EGLN2 | |
| SCHEMBL22121920 | 0.78 | CYP2C19 (0.38) | CYP2C19CYP17A1ALOX5APFEN1ELOVL1 | |
| SCHEMBL16441792 | 0.78 | KMO (0.48) | CYP17A1KMOALOX5APFEN1ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | claimed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2026-03-10 | — | — | US | disclosed |
| US-20250368667-A1 | USP1 INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-4582427-A1 | USP1 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250066348-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-02-27 | — | — | US | disclosed |
| CN-119497713-A | USP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| US-20250026754-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-119173512-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-116178279-A | Preparation method of 5-bromo-4-cyclopropyl-6-methoxypyrimidine and intermediate thereof | 上海药坦药物研究开发有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083286-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083286-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4090332-A1 | COMPOSITIONS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND USES THEREOF | KSQ Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026754-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | CYP2C19 4201/4885CYP17A1 2322/4885KMO 2704/4885 |
| US-20250368667-A1 | USP1 INHIBITOR | USP1, USP2, USP28 | CYP2C19 3537/4885CYP17A1 468/4885KMO 3818/4885 |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | CYP2C19 4100/4885CYP17A1 2258/4885KMO 2607/4885 |
| US-20250066348-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | CYP2C19 4198/4885CYP17A1 2343/4885KMO 2665/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | CYP2C19 3775/4885CYP17A1 1888/4885KMO 3480/4885 |
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | USP1, USP2, USP3 | CYP2C19 1596/4885CYP17A1 1414/4885KMO 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.